Gross Profit Comparison: Gilead Sciences, Inc. and Biogen Inc. Trends

Biotech Giants' Profit Trends: A Decade in Review

__timestamp	Biogen Inc.	Gilead Sciences, Inc.
Wednesday, January 1, 2014	8532288000	21102000000
Thursday, January 1, 2015	9523400000	28633000000
Friday, January 1, 2016	9970100000	26129000000
Sunday, January 1, 2017	10643900000	21736000000
Monday, January 1, 2018	11636600000	17274000000
Tuesday, January 1, 2019	12422500000	17774000000
Wednesday, January 1, 2020	11639400000	20117000000
Friday, January 1, 2021	8872000000	20704000000
Saturday, January 1, 2022	7895100000	21624000000
Sunday, January 1, 2023	7302200000	20618000000
Monday, January 1, 2024	9675900000	78200000

Data in motion

A Decade of Gross Profit Trends: Gilead Sciences, Inc. vs. Biogen Inc.

In the ever-evolving landscape of biotechnology, Gilead Sciences, Inc. and Biogen Inc. have been pivotal players. Over the past decade, from 2014 to 2023, these giants have showcased intriguing trends in their gross profits. Gilead Sciences, Inc. consistently outperformed Biogen Inc., with its gross profit peaking in 2015 at approximately 28.6 billion USD, a remarkable 34% higher than Biogen's peak in 2019. However, Gilead's profits saw a decline of about 28% by 2018, reflecting industry challenges. Meanwhile, Biogen's gross profit demonstrated a steady climb, reaching its zenith in 2019, before experiencing a 41% drop by 2023. This data not only highlights the competitive dynamics between these two companies but also underscores the broader economic and market forces at play in the biotech sector.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025